IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES TAKEDA
Company/Organization Date Area of
Collaboration
Takeda, Hitachi Ltd. and
Juntendo University
Faculty of Medicine
Terms of Agreement
1999 SNPs A collaboration into the identification of
SNPs. The project is being run under the
auspices of the Japan Biotechnology
Industry Consortium. Lasting for 1 year,
the project will focus on allergic diseases.
Takeda will use the information in its drug
discovery efforts. Hitachi will build a
large-scale, rapid SNP identification
system. Some 200 patients with atopic
dermatitis, and 100 healthy controls, will
be used to identify at least 10 groups of
cytokines and cytokine receptor genes.
Novo Nordisk 1996 Diabetes Research deal for the development of
compounds for diabetes. The goal is to
identify orally active drugs for controlling
blood glucose in Type 2 diabetes. NN will
contribute its expertise relating to
receptors for blood glucose regulation.
Takeda will provide a library of small
molecules with affinity for these receptors.
Human Genome Sciences,
Glaxo SmithKline
1995 Genome data,
combinatorial
chemistry
© 2009 IMS Health In cor po rated or its af fil i ates Page 107
Takeda gained access to HGS’ human
genome database and SB’s combinatorial
chemistry technology. In 2002 Takeda
exercised its option to develop and
commercialize mapatumumab in Japan;
an option fee has been paid and Takeda
will also pay milestones and royalties if the
compounds are marketed in Japan